A5100404108- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Protein purification and stability
- HER2/EGFR in Cancer Research
- RNA Interference and Gene Delivery
- Viral Infectious Diseases and Gene Expression in Insects
- Transgenic Plants and Applications
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Computational Drug Discovery Methods
- MXene and MAX Phase Materials
- Immunotherapy and Immune Responses
- Galectins and Cancer Biology
- Advanced biosensing and bioanalysis techniques
- Radiopharmaceutical Chemistry and Applications
- T-cell and B-cell Immunology
- Protein Degradation and Inhibitors
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- Renal and related cancers
- S100 Proteins and Annexins
- Complement system in diseases
- Click Chemistry and Applications
- Ocular Surface and Contact Lens
- Biotin and Related Studies
Zhengzhou University
2024
Nanjing Medical University
2012-2024
Jiangsu Province Hospital
2012-2024
China Agricultural University
2023
Tianjin Institute of Pharmaceutical Research (China)
2023
AstraZeneca (United States)
2019-2022
Hansoh Bio (United States)
2022
Sun Yat-sen University
2016-2019
Shanghai Institute of Organic Chemistry
2016-2018
Centre for Cellular and Molecular Biology
2018
Abstract RNA interference (RNAi) gene silencing technologies have shown significant potential for treating various diseases, including cancer. However, clinical success in cancer therapy remains elusive, mainly owing to suboptimal vivo delivery of RNAi therapeutics such as small (siRNA) tumors. Herein, we developed a library polymers that respond narrow pH change (ultra‐pH‐responsive), and demonstrated the utility these materials targeted deep tumor‐penetrating nanoparticle (NP) RNAi. The...
Myriad new applications of proteases would be enabled by an ability to fine-tune substrate specificity and activity. Herein we present a general strategy for engineering protease selectivity activity capitalizing on sequestration the engineered within yeast endoplasmic reticulum (ER). A fusion protein composed adhesion receptor subunit Aga2, selection counterselection sequences, multiple intervening epitope tag C - terminal ER retention sequence is coexpressed with library. Cleavage...
Efficacious use of therapeutic gene delivery via nanoparticles is hampered by the challenges associated with targeted to tissues interest. Systemic administration lipid nanoparticle (LNP)-encapsulated mRNA leads a protein expressed predominantly in liver and spleen. Here, LNP encapsulating was covalently conjugated an antibody, specifically binding plasmalemma vesicle-associated (PV1) as means target lung tissue. PV1-targeted LNPs demonstrated significantly increased lungs 40-fold...
A number of clever recombinant methodologies have been developed that recapitulate the valencies IgG's (bivalent) and IgA's (tetravalent). Although higher synthetic achieved by conjugation either monoclonal antibodies or single-chain to nanoparticles liposomes, a method for preparation with similar IgM's (decavalent) but considerably less than what is generally found after antibody particle has yet be devised. Recently, we methodology design bivalent Chemically Self-Assembled Antibody...
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against have not shown significant efficacy for tumors with overexpression. In this study, we employed bispecific antibody approach to target positive cells. A novel antibody, Muc1-Bi-1, was constructed by linking single domain antibodies, anti-Muc1-VHH and anti-CD16-VHH. Muc1-Bi-2, humanized form also grafting. Both Muc1-Bi can be efficiently expressed purified from bacteria. vitro, recruit...
An enzyme engineering technology involving yeast endoplasmic reticulum (ER) sequestration screening (YESS) has been recently developed. Here, a new method is established, in which the YESS platform combined with NextGen sequencing (NGS) to enable comprehensive survey of protease specificity. In this approach, combinatorial substrate library targeted ER and transported through secretory pathway, interacting any protease(s) residing ER. Multicolor FACS used isolate cells labeled...
Bispecific antibodies have emerged as powerful therapeutic agents given their high specificity and ability to induce a potent immune response. Various bispecific antibody formats been designed studied regarding applications in cancer therapy, though associated with issues of short half-life or manufacturing difficulties. Herein, novel antibody, SS-Fc, was constructed by pairing 2 single-domain antibodies, anti-CD16 anti-CEA, which were fused CH3 "knobs into holes" mutations individually....
Bispecific antibodies that engage immune cells to kill cancer are actively pursued in immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low molecular weight with or fragments generally leads their rapid clearance vivo, which limits therapeutic potential these antibodies.In this study, we used a site-specific PEGylation strategy modify single-domain antibody-linked (S-Fab),...
One of the most active fields in cancer immunotherapy is study bispecific antibodies, which engage immune cells to kill cells. However, a variety issues are associated with current antibody formats. In this study, we present novel antibody, BiSS (Bispecific Single domain, domain antibodies), was constructed by linking 2 single anti-CEA and anti-CD16, tandem. Unlike other can be expressed purified from E.coli large quantities. By recruiting natural killer (NK cells) CEA-positive cells, led...
Systemic administration of bio-therapeutics can result in only a fraction drug reaching targeted tissues, with the majority being distributed to tissues irrelevant drug's site action. Targeted delivery specific organs may allow for greater accumulation, better efficacy, and improved safety. We investigated how targeting plasmalemma vesicle-associated protein (PV1), found endothelial caveolae lungs kidneys, promote accumulation these organs. Using ex vivo fluorescence imaging, we show that...
Her2, which is frequently overexpressed in breast cancer, one of the most studied tumor-associated antigens for cancer therapy. Anti-HER2 monoclonal antibody, trastuzumab, has achieved significant clinical benefits metastatic cancer. In this study, we describe a novel bispecific antibody Her2-S-Fab targeting Her2 by linking single domain anti-CD16 VHH to trastuzumab Fab. The can be efficiently expressed and purified from Escherichia coli, drive potent cell killing HER2-overexpressing cells....
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific targeting natural killer (NK) cells has been studied cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. are then constructed by fusing these single domain with an anti-CEA antibody. These bispecific can recruite NK to kill CEA-positive tumor cells, inhibit growth in vivo,...
Despite some clinical success with antibody-drug conjugates (ADCs) in patients solid tumors and hematological malignancies, improvements ADC design are still desirable due to the narrow therapeutic window of these compounds. Tumor-targeting antibody fragments have distinct advantages over monoclonal antibodies, including more rapid tumor accumulation enhanced penetration, but subject clearance. Half-life extension technologies such as PEGylation albumin-binding domains (ABDs) been widely...
Getting together and breaking up: Circular arrays of recombinant antibodies can be produced reversibly by chemically controlled protein macrocyclization. In the presence bismethotrexate (bis-MTX), dimeric dihydrofolate reductase fusion (DHFR) with an anti-CD3 single-chain variable region (scFv) self-assembled spontaneously into diabodies, which were disassembled monomers excess antibiotic trimethoprim (see picture).
Monoclonal antibody (McAb) is the key tool for cancer immunodiagnosis and immunotherapy. McAb-based immunotherapy that targets tumor antigens has had great achivement. In this study, a cell clone which kept secreting high-titer IgG1-type McAb named NJ001 against human non-small lung (NSCLC) cells was obtained. The titer of purified 2×106. antigen SP70 NSCLC specifically identified by proved to be protein with relative molecular mass (Mr) 70 kDa. results immunohistochemical staining indicated...
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions designed cover the whole mAb light chain and heavy respectively used generate polyclonal antibodies after conjugation of peptides carrier protein, KLH. It was shown that good peptide specificity achieved from generated. Using more than 30 different measure surface epitope distribution, it antibody array can detect exposure as low 0.1% defined...
Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed and activated in metastatic breast cancers. Monoclonal antibodies targeting Her2, such as trastuzumab pertuzumab, have become important targeted therapies for patients with HER2-positive cancer. Both pertuzumab can reduce Her2 positive tumor burden by inhibiting signaling inducing ADCC activities (antibody dependent cell-mediated cytotoxicity). In this study, we generated a bispecific antibody, Her2(Per)-S-Fab,...
Abstract RNA interference (RNAi) gene silencing technologies have shown significant potential for treating various diseases, including cancer. However, clinical success in cancer therapy remains elusive, mainly owing to suboptimal vivo delivery of RNAi therapeutics such as small (siRNA) tumors. Herein, we developed a library polymers that respond narrow pH change (ultra‐pH‐responsive), and demonstrated the utility these materials targeted deep tumor‐penetrating nanoparticle (NP) RNAi. The...
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types cancers, which plays a vital role the cancer progression. Monoclonal antibodies targeting Her2 are now used clinic treat overexpression patients. However, relapse or resistance frequent with current therapies. To generate new treatment avenue against Her2, we immunized selected specific anti-Her2 single domain antibody C3 for further studies. The C3-Fc drove...
Annexin A1 (anxA1) is an immunomodulatory protein that has been proposed as a tumor vascular target for antitumor biologic agents, yet to date the expression of anxA1 in specific indications not systematically assessed. Attempts evaluate by immunohistochemistry are complicated lack available antibodies both and bind N-terminal–truncated form previously identified vasculature. To study pattern non–small-cell lung carcinoma (NSCLC), we isolated antibody capable binding 27-346 employed it...